HIND (Vyome Holdings) Ending Cash Position: $8.80 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HIND Vyome Holdings Inc HIND
11 GF Score
Price $1.99
! 2 Warning Signs
View Full Analysis

What is Vyome Holdings Ending Cash Position?

Vyome Holdings HIND -0.50% 11 Ending Cash Position is $8.80 Mil as of Mar. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Vyome Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 was $8.80 Mil.

Vyome Holdings's quarterly Ending Cash Position declined from Sep. 2025 ($5.32 Mil) to Dec. 2025 ($4.98 Mil) but then increased from Dec. 2025 ($4.98 Mil) to Mar. 2026 ($8.80 Mil).

Vyome Holdings's annual Ending Cash Position increased from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.10 Mil) and increased from Dec. 2024 ($0.10 Mil) to Dec. 2025 ($4.98 Mil).

Vyome Holdings Ending Cash Position Related Terms

Vyome Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vyome Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vyome Holdings Ending Cash Position Chart

Vyome Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.46 0.02 0.10 4.98

Vyome Holdings Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.33 5.32 4.98 8.80
HIND
11GF Score
Vyome Holdings Inc HIND
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vyome Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vyome Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.102+4.88
=4.98

Vyome Holdings's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.982+3.814
=8.80

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $8.80 Mil mean?
Vyome Holdings (HIND) has a Ending Cash Position of $8.80 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vyome Holdings and its competitors.
Is Vyome Holdings' Ending Cash Position too high?
Vyome Holdings' current Ending Cash Position is $8.80 Mil. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Ending Cash Position compare to CTXR and MBRX?
Vyome Holdings' Ending Cash Position of $8.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current Ending Cash Position is $8.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Ending Cash Position of $8.80 Mil. The current Ending Cash Position is $8.80 Mil. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Ending Cash Position is $8.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vyome Holdings Business Description

Address Harvard Square, Suite 400, One Mifflin Place, Cambridge, MA, USA, 02138
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score

Get the complete analysis for HIND

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price